Neurobiology of Aging
Volume 28, Issue 9 , Pages 1381-1387 , September 2007

Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease

  • Shirley W.Y. Tsang

      Affiliations

    • Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • Justine Pomakian

      Affiliations

    • Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Gad A. Marshall

      Affiliations

    • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Harry V. Vinters

      Affiliations

    • Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Jeffrey L. Cummings

      Affiliations

    • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Christopher P.L.-H. Chen

      Affiliations

    • Department of Neurology, National Neuroscience Institute, Singapore
    • ,
  • Peter T.-H. Wong

      Affiliations

    • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • Mitchell K.P. Lai

      Affiliations

    • Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    • Corresponding Author InformationCorrespondence to: Dementia Research Laboratory, Department of Clinical Research, Block 6, Level 6, Room B22, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. Tel.: +65 6321 3731; fax: +65 6225 7796.

Received 2 March 2006 ,Revised 8 April 2006 ,Accepted 2 June 2006.

References 

  1. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1994;
  2. Ali DW, Salter MW. NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr Opin Neurobiol. 2001;11:336–342
  3. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414
  4. Battaini F, Pascale A, Lucchi L, Pasinetti GM, Govoni S. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol. 1999;159:559–564
  5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239–259
  6. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med. 2000;32:210–221
  7. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671–682
  8. Caulfield MD. Muscarinic receptors—characterization, coupling and function. Pharmacol Ther. 1993;58:319–379
  9. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene. 2005;348:1–11
  10. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47:876–883
  11. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA. 2004;101:11141–11146
  12. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995;64:1888–1891
  13. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol. 1991;29:256–262
  14. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18:S15–S21
  15. Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology. 1999;38:1253–1259
  16. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:421–430
  17. Greenlee W, Clader J, Asberom T, McCombie S, Ford J, Guzik H, et al. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco. 2001;56:247–250
  18. Grosshans DR, Clayton DA, Coultrap SJ, Browning MD. LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1. Nat Neurosci. 2002;5:27–33
  19. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem. 2000;74:237–243
  20. Hynd MR, Scott HL, Dodd PR. Glutamate (NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease. J Neurochem. 2001;78:175–182
  21. Hynd MR, Scott HL, Dodd PR. Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disease. J Neurochem. 2004;90:913–919
  22. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, et al. Molecular characterization of the family of the N-methyl-d-aspartate receptor subunits. J Biol Chem. 1993;268:2836–2843
  23. Krainc D, Bai G, Okamoto S, Carles M, Kusiak JW, Brent RN, et al. Synergistic activation of the N-methyl-d-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1. J Biol Chem. 1998;273:26218–26224
  24. Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, et al. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57:805–811
  25. Laurie DJ, Seeburg PH. Ligand affinities at recombinant N-methyl-d-aspartate receptors depend on subunit composition. Eur J Pharmacol. 1994;268:335–345
  26. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, et al. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci. 1999;2:331–338
  27. MacDonald JF, Kotecha SA, Lu WY, Jackson MF. Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr Drug Targets. 2001;2:299–312
  28. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA. 1998;95:11465–11470
  29. Milner B, Squire LR, Kandel ER. Cognitive neuroscience and the study of memory. Neuron. 1998;20:445–468
  30. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology. 2000;55:1460–1467
  31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD), part II, standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  32. Mitchell JJ, Anderson KJ. Age-related changes in [3H]MK-801 binding in the Fischer 344 rat brain. Neurobiol Aging. 1998;19:259–265
  33. Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology. 1988;38:606–608
  34. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem. 1995;270:28495–28498
  35. Olariu A, Yamada K, Nabeshima T. Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators. J Pharmacol Sci. 2005;97:1–5
  36. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000;61:75–111
  37. Procter AW, Wong EH, Stratmann GC, Lowe SL, Bowen DM. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease. J Neurochem. 1989;53:698–704
  38. Scott DB, Blanpied TA, Ehlers MD. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology. 2003;45:755–767
  39. Stephenson FA. Subunit characterization of NMDA receptors. Curr Drug Targets. 2001;2:233–239
  40. Sun MK, Alkon DL. Protein kinase C isozymes: memory therapeutic potential. Curr Drug Targets CNS Neurol Disord. 2005;4:541–552
  41. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci. 1994;17:551–567
  42. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, et al. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-d-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem. 1997;272:5157–5166
  43. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging. 2006;27:1216–1223
  44. Vener AV, Aksenova MV, Burbaeva GS. Drastic reduction of the zinc- and magnesium-stimulated protein tyrosine kinase activities in Alzheimer's disease hippocampus. FEBS Lett. 1993;328:6–8
  45. Wang HY, Pisano MR, Friedman E. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol Aging. 1994;15:293–298
  46. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237–1239
  47. Wilcock GK, Esiri MM, Bowen DM, Smith CC. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci. 1982;57:407–417

PII: S0197-4580(06)00199-0

doi: 10.1016/j.neurobiolaging.2006.06.001

Neurobiology of Aging
Volume 28, Issue 9 , Pages 1381-1387 , September 2007

Article Tools

* Image Usage & Resolution